Navigation Links
Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
Date:6/6/2011

008, Regulus formed a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. In February 2010, Regulus and GlaxoSmithKline entered into a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of hepatitis C infection. In June 2010, Regulus and sanofi-aventis entered into the largest-to-date strategic alliance for the development of microRNA therapeutics. This alliance is focused initially on fibrosis. For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus, including statements regarding the therapeutic potential of targeting miR-33. Any statement describing Regulus' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulus' management, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus', A
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 CytRx Corporation ... development company specializing in oncology, today announced that ... Executive Officer, and David Haen , Vice ... present a corporate overview at two significant investment ... and healthcare industries: the FBR & Co. Second ...
(Date:9/1/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... development and sale of broadly enabling, pressure cycling ... life sciences industry, today announced the publication of ... PCT Platform could play a significant role in ... is based on PCT,s unique ability to help ...
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to ... cancer patients. , Editorial and marketing groups within OncLive, which provides oncologists ...
(Date:9/1/2015)... PA (PRWEB) , ... September 01, 2015 , ... The ... 18 at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. ... has raised more than $13.5 million for programs and services designed to support patients ...
(Date:9/1/2015)... ... 01, 2015 , ... With former IBMers among its founding members, Inmar has ... more than 35 years ago. A pilot program begun by the company in 2014 ... just those intent on pursuing careers in these fields. The program is now open ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit Inc., a leading ... the FirstSpirit Content Management System with new capabilities and enhancements designed to support ... companies will be well on their way to achieving digital transformation with less ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Zecurion, a ... Mac , its groundbreaking new version of endpoint DLP developed specifically for Mac OS. ... in which more than 100 IT and information security professionals had participated. The beta ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Zecurion Announces Endpoint Security for Mac 2
... suffer a break up to eight times more likely to die, ... and women who break a hip are five to eight times ... fracture, a new study by Belgian researchers has found. , And, ... the first two years after the break, it never returns to ...
... , MONDAY, March 15 (HealthDay News) -- A ... sexual dysfunction in people with Parkinson,s disease has been ... main symptoms of Parkinson,s disease are movement problems, but ... noted lead guidelines author Dr. Theresa A. Zesiewicz, of ...
... boomer epidemic predicted , MONDAY, March 15 (HealthDay News) -- ... the 1990s, making it by far the most common form ... two new studies find. , More than 2 million Americans ... up from 1.6 million in 1992, according to one study. ...
... ... identify infants at high risk of developing childhood-onset obesity by measuring a newborn baby’s ... possible is called the Pea Pod® Infant Body Composition System. Located at Prentice Women’s ... , ...
... (TSE: 4503) today released the following statement in response to OSI Pharmaceuticals, (Nasdaq: OSIP ) rejection of Astellas, tender offer for $52.00 per share. , ... , ... ... ...
... are focused on the issue 24/7. , ... , , ... ... Rotary is committed to helping achieve the UN Millennium Development Goal that calls for a 50 percent reduction ...
Cached Medicine News:Health News:Risk of Death Persists After a Hip Fracture 2Health News:Risk of Death Persists After a Hip Fracture 3Health News:Relief Sought for Secondary Parkinson's Symptoms 2Health News:Non-Melanoma Skin Cancers in the Millions and Rising 2Health News:Non-Melanoma Skin Cancers in the Millions and Rising 3Health News:Non-Melanoma Skin Cancers in the Millions and Rising 4Health News:Study to Identify Infants at High Risk for Developing Obesity 2Health News:Study to Identify Infants at High Risk for Developing Obesity 3Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 2Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 3Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 4Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 5Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 6Health News:Astellas Responds to OSI Pharmaceuticals' Rejection 7Health News:Rotary Clubs Always Pumped for World Water Day 2Health News:Rotary Clubs Always Pumped for World Water Day 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: